Suraksha Diagnostics Pvt Ltd signed a Memorandum of Understanding (MoU) with Kolkata Gynaecological Oncology trials & Translational Research Group (KolGOTrg) to launch the novel Homologous Recombination Deficiency (HRD) Test for the first time in diagnostics in India. This will help detect Ovarian Cancer and serve as a low-cost alternative for ovarian cancer detection in the diagnostics sector in India.

Dr. Somnath Chatterjee, Director, Suraksha Diagnostics Pvt Ltd., Dr. Asima Mukhopadhyay, HOD, Dept of Gynaecological Oncology, Chittaranjan National Cancer Institute & Founder Secretary, KolGOTrg, Consultant, BARTS, London and Dr. Abhirup Sarkar, Laboratory Director, Suraksha Diagnostics Pvt Ltd. were present for the signing of the MoU and the launch of HRD Test.

Apart from this KolGOTrg is also collaborating with Suraksha Diagnostics for the Department of Science & Technology grant on Translational research on HIPEC, an updated surgical technique for ovarian cancer patients.

The HRD Test will be priced between Rs 5,000/- to Rs 10,000/- and will be available at Suraksha Diagnostics Centre at Sector 1 PLOT NO-DD 18, 1, Bidhannagar, Kolkata – 700064.